A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
Trial details
- Registry ID
- NCT05273749
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Low dose cyclobenzaprine sublingual tablets
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With FibromyalgiaNCT05273749 | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 2023-11-14Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |